JAMA子刊:肾移植和肝移植孕妈临产:选顺产试产还是直接剖宫产?

2021-10-28 MedSci原创 MedSci原创

与计划性剖宫产术相比,分娩试验能改善新生儿结局,而并不增加母体严重并发症的发病率。

剖宫产(CD)是分娩时最常见的手术操作,占2018年美国产科分娩的31.9%,与CD相关的孕妇并发症包括输血、子宫切除术、产妇出血风险增加、感染、静脉血栓栓塞等,新生儿并发症包括呼吸系统疾病和新生儿重症监护病房(NICU)入院病症等。由于逐步认识到这些风险,临床上开始降低非医学指证的CD然而,近些年来器官移植患者的CD率越来越高,有必要研究器官移植患者CD的适应症,以确定最安全的产科分娩方式。

这项回顾性队列研究使用了国际移植妊娠注册中心的数据,选取近50年(1968-2019)接受肾脏和肝脏移植的1865名女性来做数据分析研究。数据分析时间为2020年4月30日至2021年4月16日。

参与者的年龄范围为18至48岁,受试者的中位体重指数在正常范围内,接受移植的中位时间间隔超过2年。与计划CD相比,试产(TOL)与肾移植受者的严重孕产妇发病率增加无关。总的来说,459名肾移植受者中有229名(49.9%)和105名肝移植受者中有50名(47.6%)因非药物适应症或重复适应症进行了预定的CDs,尽管有这些适应症的妇女是TOL的候选对象。

肾和肝移植受者分娩方式对产科和移植结局的多因素分析表

在这项队列研究中,研究者没有发现与分娩试验(TOL)相关的孕产妇发病率增加,尤其是分娩期间高血压疾病恶化导致的急性肾功能衰竭、子痫、肺水肿、中风或血管并发症风险增加。与计划性剖宫产术相比,分娩试验能改善新生儿结局,而并不增加母体严重并发症的发病率。为了降低器官移植后CD的发病率,可能需要在多个层面进行改革,包括产科和移植团队支持、分娩单位和医院政策改进以及国家和国际支持。在患者的移植中心建立孕前和产前护理可以促进TOL期间更好的跨学科沟通和管理

参考文献:Yin O, Kallapur A, Coscia L, et al. Mode of Obstetric Delivery in Kidney and Liver Transplant Recipients and Associated Maternal, Neonatal, and Graft Morbidity During 5 Decades of Clinical Practice. JAMA Netw Open. 2021;4(10):e2127378. doi:10.1001/jamanetworkopen.2021.27378

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1183857, encodeId=95ba118385e42, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5d3045764, createdName=729787690, createdTime=Thu Jan 13 12:13:57 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074789, encodeId=e48b10e47896c, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adfa3246155, createdName=12cdce52m85暂无昵称, createdTime=Sun Nov 28 16:13:02 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066381, encodeId=c3ae10663816e, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=502a5654182, createdName=Betty-贝, createdTime=Tue Nov 02 21:48:03 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064689, encodeId=28b9106468943, content=太厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9245651352, createdName=ms5000001675894924, createdTime=Thu Oct 28 15:15:04 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2022-01-13 729787690

    有用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1183857, encodeId=95ba118385e42, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5d3045764, createdName=729787690, createdTime=Thu Jan 13 12:13:57 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074789, encodeId=e48b10e47896c, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adfa3246155, createdName=12cdce52m85暂无昵称, createdTime=Sun Nov 28 16:13:02 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066381, encodeId=c3ae10663816e, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=502a5654182, createdName=Betty-贝, createdTime=Tue Nov 02 21:48:03 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064689, encodeId=28b9106468943, content=太厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9245651352, createdName=ms5000001675894924, createdTime=Thu Oct 28 15:15:04 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2021-11-28 12cdce52m85暂无昵称

    厉害

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1183857, encodeId=95ba118385e42, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5d3045764, createdName=729787690, createdTime=Thu Jan 13 12:13:57 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074789, encodeId=e48b10e47896c, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adfa3246155, createdName=12cdce52m85暂无昵称, createdTime=Sun Nov 28 16:13:02 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066381, encodeId=c3ae10663816e, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=502a5654182, createdName=Betty-贝, createdTime=Tue Nov 02 21:48:03 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064689, encodeId=28b9106468943, content=太厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9245651352, createdName=ms5000001675894924, createdTime=Thu Oct 28 15:15:04 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2021-11-02 Betty-贝

    厉害

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1183857, encodeId=95ba118385e42, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5d3045764, createdName=729787690, createdTime=Thu Jan 13 12:13:57 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074789, encodeId=e48b10e47896c, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adfa3246155, createdName=12cdce52m85暂无昵称, createdTime=Sun Nov 28 16:13:02 CST 2021, time=2021-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066381, encodeId=c3ae10663816e, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=502a5654182, createdName=Betty-贝, createdTime=Tue Nov 02 21:48:03 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064689, encodeId=28b9106468943, content=太厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9245651352, createdName=ms5000001675894924, createdTime=Thu Oct 28 15:15:04 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2021-10-28 ms5000001675894924

    太厉害了

    0

相关资讯

Diabetes Care:肾移植受者水果和蔬菜摄入量与移植后糖尿病风险

在这项研究中,蔬菜摄入量,而不是水果摄入量,与RTR的PTDM风险降低相关,可能主要是通过对代谢综合征关键组分的有益作用。这些发现进一步支持RTR提高蔬菜摄入量的建议。

Lancet Dia& Endo:雷米普利不能改善肾移植受者的临床结果

血管紧张素转换酶抑制剂已经显示,可减少终末期肾脏疾病和蛋白尿非移植患者死亡的危险。研究人员研究了雷米普利是否会对蛋白尿肾移植受者重要的临床结果有相似的有利影响。这项双盲,安慰剂对照,随机临床试验,在加拿大和新西兰的14个中心进行,研究人员共招募了招收肾移植术后至少3个月的成人肾移植受者,估计肾小球滤过率(GFR)为20 mL/min/1.73 m2或更大,蛋白尿为每天0.2克或更大,他们被随机分配

中国肾移植受者哺乳动物雷帕霉素靶蛋白抑制剂临床应用专家共识

哺乳动物雷帕霉素靶蛋白抑制剂(mammalian target of rapamycin inhibitors,mTORi)作为免疫抑制剂在临床应用已经有10多年的历史, 目前用于移植后免疫抑制治疗的mTORi主要包括西罗莫司(sirolimus,SRL)和依维莫司(everolimus,EVL),其他mTORi,如坦西莫司等仅用于抗肿瘤治疗。哺乳动物雷帕霉素靶蛋白(mTOR)是丝氨酸-苏氨酸蛋白